Ibopamine

Ophthalmic
Mydriasis

Oral
Mild heart failure

Oral: Severe heart failure, phaeochromocytoma. Ophthalmic: Angle-closure glaucoma.

CV diseases; hyperthyroidism; DM; elderly; pregnancy, lactation; prostate disorders; occlusive vascular disease; cardiac arrhythmias.

Palpitations, tachycardia, arrhythmias, reflex bradycardia. Hypotension, dizziness, fainting. Anxiety, fear, restlessness, insomnia, confusion, irritability, headache, psychotic symptoms. Dyspnoea, weakness, anorexia, nausea, vomiting. Mydriasis, difficulty in micturition and urinary retention, piloerection, sweating, increased salivation. Hyperglycaemia. Hypokalaemia and muscle tremor.

Increased cardiac effects with volatile anaesthetics, thyroid hormones, cardiac glycosides and antiarrhythmics. Additive hypotensive effects with antihypertensives. Severe hypotension may occur with guanethidine. Increased risk of hypotension and tachycardia with α-blockers. Increased risk of hypertension with nonselective β-beta blockers. Increased risk of hypertension and arrhythmias with TCAs. Additive CV toxicity with levodopa, bromocriptine.
Potentially Fatal: Increased risk of mortality with amiodarone (although interaction is not established).

Description: Ibopamine is a peripheral dopamine agonist with vasodilating properties and a weak positive inotropic effect. It stimulates α- and β-adrenoceptors at high concentrations.
Pharmacokinetics:
Absorption: Peak plasma concentrations after 30 min (oral).
Metabolism: Rapidly converted to epinene (active metabolite) by esterase hydrolysis.

Cardiac Drugs / Mydriatic Drugs